New Interventions For Managing Asthma

New Interventions For Managing Asthma

Asthma is considered to be a chronic Obstructive pulmonary disease (COPD) whereby there is an obstruction in the constant airflow in the lungs with symptoms such as coughing, wheezing and dyspnea, seen prominently. These symptoms become worse if patients With asthma are exposed to substance they are sensitive to, or put in situations that changes their regular pattern of breathing.

Managing Asthma

Patients with asthma require both oral and written advice which can guide them to recognize the signs and symptoms of asthma and how to manage it when it is worsening. By the medium of education, one can help the patient to gain confidence to contain asthma.

Stepwise Progressive Management
The study conducted by GOAL utilizing separate therapies and combinations have discovered the possibility of attaining total control of asthma, The study shows that by extending the combination therapy for three months abolishes uncontrolled asthma symptoms. The benefit of combination therapy lies in the ability to control asthma with low corticosteroid doses while decreasing the number of inhalers.

SMART (Single Maintenance And Reliever Therapy)
The potential advantage of SMART strategy lies in One fact that the patient will simultaneously receive additional doses of inhaled corticosteroids along with a bronchodilator when used with a combined inhaler for relief from a symptom This Will target anti-inflammatory cells to treat periods of poorly controlled asthma.

Airway Inflammation Assessment
In order to monitor airway inflammation, the usage of non-invasive biomarkers have administered an alternative method to patient-driven symptom management for the assessment of asthma. With the non-invasive airway sampling technique, patients with a chronic cough and refractory asthma can be managed and airway inflammation can be assessed too.

Other Novel Therapeutic Options

These options include thermal bronchoplasty, antifungal agents, tumor necrosis factor-alpha or IL-5 and monoclonal antibodies targeting lgE. However, due to their invasive nature, adverse side effects and cost. these treatments play a limited role in the management of patients with asthma and is usually followed in patients with difficulty related to asthma.

Leave a Comment